Gayathri Kallukaran is a Junior Journalist with Eastern Eye. She has a Master’s degree in Journalism and Mass Communication from St. Paul’s College, Bengaluru, and brings over five years of experience in content creation, including two years in digital journalism. She covers stories across culture, lifestyle, travel, health, and technology, with a creative yet fact-driven approach to reporting. Known for her sensitivity towards human interest narratives, Gayathri’s storytelling often aims to inform, inspire, and empower. Her journey began as a layout designer and reporter for her college’s daily newsletter, where she also contributed short films and editorial features. Since then, she has worked with platforms like FWD Media, Pepper Content, and Petrons.com, where several of her interviews and features have gained spotlight recognition. Fluent in English, Malayalam, Tamil, and Hindi, she writes in English and Malayalam, continuing to explore inclusive, people-focused storytelling in the digital space.
Ozempic, the blockbuster weight-loss medication that has surged in popularity across the United States and among celebrities, is now being linked to a new and unexpected side effect like sagging skin on the feet, informally dubbed “Ozempic feet”.
Medical experts say the condition is caused by rapid fat loss, which not only alters the appearance of the face and buttocks, but can also lead to aesthetic changes in the feet. As the drug continues to make headlines for its weight-loss benefits, concerns about such side effects are also gaining attention.
What is ‘Ozempic feet’?
‘Ozempic feet’ refers to sagging, wrinkled, or aged-looking skin on the feet due to dramatic reductions in body fat. The condition is considered a cosmetic side effect of the drug and is now being mentioned alongside previously reported terms like “Ozempic face” and “Ozempic butt”.
The top of the foot contains thinner, more delicate skin and less fat compared to the soles, making it more vulnerable to noticeable changes during significant weight loss. According to Dr Barry Weintraub, a board-certified plastic surgeon based in New York, losing fat can reduce water retention in the body, which may lead to excessive skin sagging and expose the underlying structures like veins and tendons.
As individuals shed large amounts of weight, particularly with the help of GLP-1 drugs like Ozempic and Mounjaro, their feet may begin to appear older, more wrinkled, and veiny.
Celebrities showing signs?
Fans have recently speculated that celebrities including Sharon Osbourne and Oprah Winfrey might be exhibiting signs of this side effect. Both have publicly spoken about using weight-loss drugs, though neither has directly commented on ‘Ozempic feet’.
Sharon Osbourne, 72, posted a photo with her grandson on Instagram earlier this month, prompting some commenters to note the sharp contrast between her smooth, youthful face and the visibly veiny and aged appearance of her feet. While some suggested the image had been airbrushed, the feet, according to users, revealed signs of extreme weight loss.
Dr Weintraub, while not having examined Osbourne in person, suggested the skin changes could be the result of reduced water retention and fat stores, common outcomes of weight loss induced by GLP-1 drugs. Osbourne has previously revealed she stopped taking Ozempic because she was losing too much weight.
Similarly, Oprah Winfrey, 71, has admitted to using a GLP-1 drug, though not specifically naming Ozempic, to assist in her weight-loss journey. She reportedly lost nearly 50 pounds and stepped down as an ambassador for Weight Watchers after revealing her use of medication. Winfrey described the drug as a “maintenance tool” rather than a quick fix for weight loss.
During her appearance at the 55th NAACP Image Awards in February, observers noted that the skin on the top of her feet looked looser and more wrinkled, further fuelling speculation that she, too, may be experiencing ‘Ozempic feet’. Winfrey has not commented on the potential side effects but has been vocal about her decades-long struggle with weight management.
How common is this?
While the term “Ozempic feet” is relatively new and informal, it’s part of a broader trend of aesthetic concerns stemming from rapid weight loss caused by GLP-1 drugs. In 2024, it was estimated that at least one in eight Americans had taken a GLP-1 medication such as Ozempic or Mounjaro. Although these drugs are primarily approved to treat type 2 diabetes, they are frequently prescribed off-label for weight loss.
The growing popularity of these drugs has brought attention to various unintended side effects. “Ozempic face” describes the gaunt, hollow look seen in the cheeks and eyes of some users, while “Ozempic butt” refers to a visibly flattened or shrunken appearance of the backside. Users have reported their buttocks becoming so diminished in volume that they feel bony and uncomfortable, leading some to hide the area out of self-consciousness.
Celebrities such as Katy Perry, Scott Disick, and Jessica Simpson have been publicly speculated to be showing signs of ‘Ozempic face’ after being photographed with noticeably leaner facial features.
Can it be treated?
In response to these cosmetic concerns, Dr Weintraub says treatments are available. A “foot lift” procedure can tighten loose skin, with incisions made along the sides of the foot to minimise visibility. Additionally, a newer injectable treatment called Skinvive, designed more as a skin plumper than a traditional filler, can be used to restore volume and smooth out the appearance of veiny or wrinkled skin, much like how similar treatments are used on the hands.
Though such procedures are still relatively uncommon, they may gain popularity if the aesthetic side effects of weight-loss drugs continue to affect users at scale.
The osmetic drawbacks
While Ozempic and similar drugs have helped many people, including high-profile figures, lose weight effectively, the cosmetic drawbacks are becoming more noticeable. As more individuals turn to medical weight loss solutions, healthcare professionals are urging users to weigh the benefits against the potential physical and visual changes that may occur.
For some, these effects may be minor or even acceptable in the pursuit of improved health. For others, especially in the public eye, the aesthetic changes may raise concerns, and in some cases, prompt a halt in usage.
As the popularity of GLP-1 drugs continues to rise, medical professionals are calling for increased awareness of all side effects, not just the internal or metabolic ones, but also the external, cosmetic changes that are now increasingly coming to light.
WHEN broadcaster and journalist Naga Munchetty began speaking openly about her experiences with adenomyosis and debilitating menstrual pain, the response was overwhelming.
Emails and messages poured in from women who had endured years of dismissal, silence and shame when it came to their health. That outpouring became the driving force behind her new book, It’s Probably Nothing, which calls for women to be heard and to advocate for themselves in a medical system that has too often ignored them.
“For so long, so many women haven’t been listened to by the world of medicine,” Munchetty said. “I knew this from my own experience of not being given adequate pain relief, or waiting years for a diagnosis. My motivation was to help women and people who love women to advocate better for women’s health.”
The book blends Munchetty’s personal journey with the voices of other women who have faced similar struggles, alongside expert insights from medical professionals. Its purpose, she said, is clear: to empower people to fight for their health.
“We need to be unafraid of saying how we have been weakened by our symptoms,” the BBC presenter said.
“Too often, we try to keep afloat, keep our head above water, but we don’t want to seem weak. That needs to change.”
Munchetty’s candour is striking. She describes the shame of being told her excruciating periods were “just normal,” leaving her to feel weak and whiny for struggling.
“You might as well have told me people have heart attacks while I’m having a heart attack,” she said. “Debilitating pain is serious — it may not be lifelimiting, but it is life-impacting.”
Her determination to challenge that culture led to her giving evidence in parliament, contributing to what became a Women and Equalities Committee report, published in December 2024.
The report made headlines for its stark conclusion: medical misogyny exists.
For Munchetty, seeing that phrase in black and white was transformative. “It was almost self-affirming,” she said. “We now know it’s there, so we can challenge it. Women can say: I know my body, I know there’s not enough research, and I am entitled to push for answers.”
The parliamentary report went further than acknowledgement. It called for ring-fenced funding for women’s health hubs, better training for GPs, and greater investment in research into reproductive conditions like adenomyosis and endometriosis.
It highlighted how symptoms are routinely dismissed as “normal,” delaying diagnosis and disrupting women’s careers, education and daily lives. Munchetty wrote in her book — referencing the report — that medical misogyny is not about blaming individual doctors, but about challenging a system built on insufficient research into women’s bodies.
“It gives women the language and the confidence to not just be heard, but to insist on being taken seriously,” she wrote.
Her book also tackles the additional barriers faced by women from minority communities, who may be discouraged by stigma or embarrassment from speaking about menstruation or menopause. To them, Munchetty has a clear message: “You are so much more valuable than you realise. If you don’t prioritise your health, you are lessening your ability to hold up everyone around you.”
Those featured in the book are friends, colleagues, charities and everyday women who contributed their stories, many for the first time. “I was surprised at how many friends are in that book with such powerful experiences,” Munchetty said.
“It told me all the more that we’re not speaking about it, and that it is sadly so very common.”
At a launch event for the book, contributors, family and experts filled the room with what Munchetty describes as an “electric and inspiring atmosphere.”
She said, “It was full of joy, of women who felt safe to speak up and be heard. This is not a whiny book — it’s a positive book. People felt they were part of making things better, part of this women’s health revolution.”
For Munchetty, writing the book was exhausting, but transformative, she said.
“I never thought I’d be an author. I’m a journalist. But this is journalism — facilitating people’s stories to be told powerfully and truthfully. People trusted me, and I’m proud of that.”
And Munchetty’s aim is for the book to be a tool for change: arming women with the language, confidence and strategies to advocate for their health.
“It’s not easy to admit you need help, and it’s not instinctive for women to prioritise themselves,” she said. “But this book will help you do that. It’s the silent friend who has your back and gives you strength.”
It’s Probably Nothing - Critical Conversations on the Women’s Health Crisis is now available in all good bookshops
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.
Williams explained that her weight challenges began after the birth of her first daughter
Serena Williams reveals she has lost more than 31lbs using a GLP-1 medication
The tennis legend says the treatment enhanced her existing healthy lifestyle
She stresses that weight loss should not change self-image or self-confidence
Serena Williams has revealed she has lost more than 31lbs after turning to a weight-loss medication, saying the treatment has transformed both her body and her mindset.
The 23-time Grand Slam champion, 43, told PEOPLE that using a GLP-1 medication — a type of injection that works by regulating appetite — has helped enhance the healthy lifestyle she already maintained through diet and exercise.
“I feel great,” Williams said. “I feel really good and healthy. I feel light physically and light mentally.”
Postpartum struggles
Williams explained that her weight challenges began after the birth of her first daughter, Alexis Olympia, in 2017. Despite training intensively and eating healthily, she found it difficult to return to her preferred weight.
“I never was able to get to the weight I needed to be, no matter what I did, no matter how much I trained,” she admitted. “It was frustrating to work so hard and not see results.”
She experienced the same plateau after giving birth to her second daughter, Adira River, in 2023. Although she initially shed weight quickly, progress soon stalled. “I never lost another pound,” she recalled.
Turning to treatment
Determined to try a new approach, Williams consulted doctors through Ro, a direct-to-patient healthcare company, and began a GLP-1 course once she had finished breastfeeding. The medication, also known as a glucagon-like peptide-1 receptor agonist, is commonly marketed under brand names such as Ozempic and Mounjaro.
“I did a lot of research before I started,” she explained. “I wanted to know if it was a shortcut or if it could really help me. In the end, it felt like the right decision.”
Williams, who is now a patient ambassador for Ro, said the injections made a noticeable difference. “I lost over 31 pounds and was really excited about that weight loss.”
Feeling better than ever
The Olympic gold medallist says she now feels stronger and more energetic.
“I can do more. I’m more active. My joints don’t hurt as much. Even simple things like moving around are easier. I feel like I have a lot more energy.”
She emphasised that GLP-1 was not a substitute for discipline but a way to support her existing healthy habits. “GLP-1 helped me enhance everything I was already doing — eating healthy and working out, whether as a professional athlete or just at the gym every day.”
Confidence and body positivity
Despite her transformation, Williams stressed that her self-confidence has never depended on her size.
“Weight loss should never really change your self-image,” she said. “Women are judged about their bodies at any size, and I’m no stranger to that. I’ve always loved myself at every stage. The difference was that my body didn’t feel good carrying that extra weight after having children.”
She added that she encourages her daughters to embrace body confidence too. “It’s important to teach them to be confident at any size, just as I try to be. Looking back, whether I was smaller or heavier, I always felt confident — and I looked great too.”
Looking ahead
Williams says she plans to continue with the weekly GLP-1 injections as needed, alongside training for a half marathon. The gym remains her “favourite place to be” — and she intends to keep sharing her workouts with fans online.
“I just feel pretty good about it all,” she said.
Keep ReadingShow less
Seles first began noticing symptoms around five years ago
Nine-time Grand Slam winner Monica Seles diagnosed with myasthenia gravis three years ago
The 51-year-old revealed her condition ahead of this month’s US Open to raise awareness
Disease causes muscle weakness and has no known cure
Former world number one Monica Seles has revealed she was diagnosed with myasthenia gravis, a rare neuromuscular autoimmune disease, three years ago. The 51-year-old, who won nine Grand Slam singles titles, went public ahead of the US Open to raise awareness of the condition, which causes muscle weakness and can affect multiple parts of the body.
Symptoms and diagnosis
Seles first began noticing symptoms around five years ago when she experienced double vision and struggled with coordination. “I would be playing [tennis] with some kids or family members, and I would miss a ball. I was like, ‘Yeah, I see two balls,’” she told the Associated Press. These symptoms eventually led to her diagnosis, which took time for her to come to terms with.
Living with the condition
The former tennis star described the impact of the disease on her daily life as “significant” and said it was initially difficult to discuss openly. Myasthenia gravis currently has no cure, but treatments can help manage its effects. By sharing her experience, Seles hopes to use her platform to educate others.
Career highlights
Seles rose to prominence as a teenager, winning her first Grand Slam at the 1990 French Open aged 16 and claiming eight majors by 19. Her career was interrupted in 1993 when she was stabbed by a spectator during a match in Hamburg. She returned to the sport and won one more Grand Slam before retiring in 2003, having spent 178 weeks as world number one and capturing 53 career titles.
NexGen knee implant linked to high failure rates was used in over 10,000 UK operations.
Concerns flagged as early as 2014; withdrawn from UK market in 2022.
Hundreds of patients required corrective surgery, with costs running into millions.
Manufacturer Zimmer Biomet says patient safety is its “top priority” but will not cover revision costs up front.
Implant used despite early warnings
A knee replacement implant used in thousands of NHS operations was known to have a concerning failure rate eight years before it was withdrawn, a BBC File on 4 Investigates report has found.
The NexGen implant, made by US manufacturer Zimmer Biomet, was fitted in more than 10,000 patients between 2012 and 2022. Concerns were first raised by the National Joint Registry (NJR) in 2014, though insufficient data at the time made it difficult to draw firm conclusions.
The model in question included a modified “stemmed option tibial component” or “tibial tray”, lacking a layer of plastic found in earlier versions. It was marketed as a cheaper alternative for the NHS.
Patients left in pain and needing further surgery
Patients have reported severe complications after their implants slipped out of place, damaging bone and causing lasting mobility issues.
Debbie Booker, from Southampton, experienced severe pain a year after her 2016 surgery, eventually requiring a second knee replacement. She says the failed implant left her addicted to strong painkillers and caused long-term health problems, including the need for a hip replacement.
Another patient, “Diana”, had her implant fitted in 2021. When it slipped and began wearing away her shin bone, her consultant told her she was “standing on a broken leg”.
Surgeons raised repeated concerns
Irish knee surgeon Prof Eric Masterson reported a surge in corrective surgeries after switching to the NexGen implant in 2012. He says his concerns were dismissed by Zimmer Biomet representatives, a view echoed by NHS surgeons.
UK knee specialist Prof Leila Biant said she and colleagues raised warnings as early as 2017, but the company was slow to engage in evaluating affected patients.
Recall and high revision costs
By 2022, NJR data suggested patients with the NexGen implant were almost twice as likely to require corrective surgery compared with the average knee replacement. Zimmer Biomet recalled unused units from the UK market that year.
Studies have estimated failure rates for the tibial tray component between 6% and 19%. Hundreds of patients have undergone revision surgery, with more expected.
Each corrective procedure costs between £10,000 and £30,000, according to Southampton University’s Prof David Barrett, meaning the total bill is likely to run into millions. Zimmer Biomet has told sales staff it will not cover diagnostic, follow-up, or revision costs up front.
Official responses
Zimmer Biomet says it is “committed to the highest standards of patient safety, quality, and transparency” and acts in line with regulations when new data becomes available.
NHS England has confirmed it is “currently reviewing the case involving Zimmer Biomet NexGen knee implants”.
Keep ReadingShow less
A 34-year-old woman developed 43 aggressive skin cancer lesions triggered by HPV
HPV, a common STI, is now potentially linked to a deadly form of skin cancer
A 34-year-old woman developed 43 aggressive skin cancer lesions triggered by HPV
Researchers say this discovery could shift the approach to diagnosing and treating some skin cancers
Protection measures include vaccination, safe sex practices, and regular screening
Human papillomavirus (HPV), one of the most widespread sexually transmitted infections in the UK, is already associated with several serious cancers — cervical, throat, penile, anal, and head and neck cancers among them. Now, researchers in the US have raised concerns that it may also contribute to certain forms of skin cancer, especially in people with weakened immune systems.
Scientists from the National Institutes of Health (NIH) found signs of beta-HPV triggering squamous cell carcinoma in a young woman who had no major history of sun damage or other typical causes.
Case study reveals viral link to aggressive skin cancer
The patient, a 34-year-old woman, was referred to NIH after developing 43 lesions of squamous cell carcinoma on her face, legs, and hands. Despite undergoing surgery and immunotherapy, the cancer repeatedly returned.
Initial suspicions pointed to sun exposure and immune deficiency, but further investigation revealed that beta-HPV had inserted its genetic material into her skin cells’ DNA, enabling the virus to take over and fuel cancer growth.
Dr Andrea Lisco, a virologist and lead author of the study, said:
"This discovery could completely change how we think about the development, and consequently the treatment, of [skin cancer] in people who have a health condition that compromises immune function."
The woman was eventually diagnosed with a genetic immune disorder that left her T-cells – vital immune system fighters – impaired. After receiving a stem cell transplant to restore immune function, her skin cancer disappeared and other HPV-related symptoms, including growths on her tongue and skin, also resolved.
The findings were published in the New England Journal of Medicine. While they are preliminary, the research adds to the growing concern about HPV’s role in cancer development beyond the cervix or throat.
3 ways to reduce the risk of HPV-linked conditions
1. Get the HPV vaccine
The HPV vaccine is the most effective protection available. In the UK, it is routinely offered to all children aged 12 to 13, but those who missed it – particularly individuals at higher risk – can still get vaccinated. It is most beneficial before sexual activity begins, but remains helpful afterward.
2. Practise safer sex
Using condoms or dental dams during vaginal, anal and oral sex can significantly reduce the risk of transmission, although not entirely, as HPV spreads through skin-to-skin contact. Maintaining a mutually monogamous relationship can also help lower exposure risk.
3. Undergo regular screenings
Routine screening, especially for women, is crucial. Pap tests and HPV tests help detect abnormal changes in the cervix early, reducing the chance of progression to cervical cancer. Current guidelines recommend starting screening at age 21 and continuing up to age 65.